Myriad Genetics, Inc. (LON:0K3W)

Market Cap	373.78M
Revenue (ttm)	643.42M
Net Income (ttm)	-78.48M
Shares Out	n/a
EPS (ttm)	-0.87
PE Ratio	n/a
Forward PE	155.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42
Average Volume	1,901
Open	5.58
Previous Close	n/a
Day's Range	5.47 - 5.58
52-Week Range	3.81 - 29.08
Beta	1.78
RSI	58.31
Earnings Date	Aug 5, 2025

About Myriad Genetics

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and meta...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1991
• Employees: 2,700
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K3W

Financial Performance

In 2024, Myriad Genetics's revenue was $837.60 million, an increase of 11.21% compared to the previous year's $753.20 million. Losses were -$127.30 million, -51.65% less than in 2023.

Financial numbers in USD